BiotechTube

AGS-1C4D4 + gemcitabine

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreatic Cancer

Conditions

Pancreatic Cancer, Carcinoma, Pancreatic Ductal, Pancreatic Disease

Trial Timeline

Aug 7, 2012 → Nov 16, 2015

NCT ID
NCT01608711

About AGS-1C4D4 + gemcitabine

AGS-1C4D4 + gemcitabine is a phase 2 stage product being developed by Astellas Pharma for Pancreatic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01608711. Target conditions include Pancreatic Cancer, Carcinoma, Pancreatic Ductal, Pancreatic Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT01608711Phase 2Completed
NCT00902291Phase 2Completed

Competing Products

20 competing products in Pancreatic Cancer

See all competitors
ProductCompanyStageHype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
pemetrexedEli LillyPhase 2
52
mFOLFIRINOX + RamucirumabEli LillyPhase 2
52
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
enzastaurin + gemcitabineEli LillyPhase 2
52
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4Eli LillyPhase 1
33
RamucirumabEli LillyPhase 1/2
41
GEMZAR + ALIMTAEli LillyPhase 3
77
CS-1008 (humanized anti-DR5 antibody) + gemcitabineDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
exatecan mesylate + gemcitabine hydrochlorideDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
erlotinib + gemcitabine + nab-paclitaxelAstellas PharmaPhase 1
33
erlotinib hydrochloride + gemcitabine hydrochlorideAstellas PharmaPhase 1
33
AGS-1C4D4 + GemcitabineAstellas PharmaPhase 2
52
Tarceva (erlotinib HCl, OSI-774)Astellas PharmaPhase 3
77
Enzalutamide + Gemcitabine + Nab-paclitaxelAstellas PharmaPhase 1
33
ASP2138 + Oxaliplatin + Leucovorin + 5-FU + Irinotecan + Gemcitabine + Nab-paclitaxel + CapecitabineAstellas PharmaPhase 1
33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85